Navigation Links
NeurogesX Receives Notice of Allowance for Patent Covering NGX-1998 Capsaicin Topical Liquid
Date:4/28/2011

SAN MATEO, Calif., April 28, 2011 /PRNewswire/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent entitled, "Methods and Compositions for Administration of TRPV1 Agonists."  The allowed claims include method of use, formulation and system claims.  The patent scheduled to issue from this application is expected to expire in 2024, with additional patent term expected in excess of approximately two years due to Patent Term Adjustment.

Anthony DiTonno, President and CEO, commented, "We believe that the Notice of Allowance for our second generation product is very significant and welcome news.  The target product profile for NGX-1998 includes similar efficacy, but a greatly reduced treatment time for NGX-1998 when compared to Qutenza®.  We believe that NGX-1998 has the potential to be a successful product in neuropathic pain, if approved for marketing, and that the granting of this patent will provide us with long-term protection for this product candidate."  

Similar claims have been issued to NeurogesX in a Eurasian patent.  The Company also received a Notice of Allowance in a related Canadian patent application.

Other Recent Patent Issuances

NeurogesX continues to be focused on developing the underlying intellectual property that supports its current and potential future product families, both in the United States and major markets throughout the world.  Since 2009, the Company has been granted patents covering capsaicin-related products such as capsaicin prodrugs, capsaicin oils, a skin cleansing gel and a specific type of capsaicin patch.  Recent patent issuances include the following:  

  • Patents relating to capsaicin prodrugs entitled, "TRPV1 Agonist Compounds and Methods for Making and Using the Same," have issued in the United Stated and Mexico.

  • Patents relating to capsaicin oils entitled, "Oils of Capsaicinoids and Methods of Making and Using the Same," have issued in the United States, throughout Europe and Eurasia.

  • With respect to the skin cleansing gel, which is a component of the Qutenza treatment kit and is used to remove residual capsaicin from the skin after a Qutenza treatment, patents entitled, "Compositions and Kits for the Removal of Irritating Compounds from Bodily Surfaces," have issued in Eurasia and Japan.  

  • A patent relating to a capsaicin patch including specific penetration enhancers entitled, "Device for Delivery of TRPV1 Agonists," has issued in South Africa.

About NeurogesX, Inc.

NeurogesX, Inc. (Nasdaq: NGSX) is a San Francisco Bay Area-based biopharmaceutical company focused on developing and commercializing novel pain management therapies. NeurogesX was founded on the concept that use of prescription-strength capsaicin could help manage the pain associated with neuropathic pain conditions. Since its inception, NeurogesX has leveraged its passion to help people with pain to efficiently develop this concept, resulting in the commercial launch of Qutenza® (capsaicin) 8% patch in 2010. The Company continues to apply its knowledge and expertise in the development of other novel treatments for pain.

The Company's lead product, Qutenza®, is a localized dermal delivery system containing prescription strength capsaicin that is currently approved in the United States and the European Union. Qutenza® is now available in the United States for the management of neuropathic pain associated with postherpetic neuralgia (PHN). In Europe, Qutenza® is being marketed by Astellas Pharma Europe Ltd. (Astellas), the European subsidiary of Tokyo-based Astellas Pharma Inc., for the treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain.

The Company is currently preparing to submit a supplemental new drug application (sNDA) to expand the U.S. label for Qutenza® for the management of pain due to HIV-associated neuropathy (HIV-AN) also known as HIV-distal sensory polyneuropathy (HIV-DSP).

The Company's most advanced product candidate, NGX-1998, is a topically applied liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions such as PHN. NGX-1998 has completed three Phase 1 studies and patient dosing is underway in a Phase 2 clinical trial in PHN patients.

The Company's early-stage pipeline includes pre-clinical compounds which are prodrugs of acetaminophen and various opioids. The Company has evaluated certain of these compounds in vitro and in vivo.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the Act). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include but are not limited to: statements regarding the submission of a supplemental new drug application for label expansion of Qutenza, the expected issuance, scope and term of the patent expected to be issued to NeurogesX, the benefits of NGX-1998 over Qutenza, the commercial potential of NGX-1998 and the duration of protection that may result from the expected patent issuance.  Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: difficulties or delays in the development of NGX-1998 and obtaining marketing approval for NGX-1998, difficulties or delays in the commercialization of Qutenza®, physician or patient reluctance to use Qutenza® or other products developed by NeurogesX despite the Company's commercialization efforts and strategies, difficulties or delays in the further development of Qutenza® for additional indications, and difficulties in maintaining patents and patent protection for NeurogesX products and product candidates. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

NeurogesX, Inc.

Stephen Ghiglieri

Executive Vice President, COO

and CFO

(650) 358-3310




The Ruth Group

Stephanie Carrington (investors)

(646) 536-7017

scarrington@theruthgroup.com


Jason Rando (media)

(646) 536-7025

jrando@theruthgroup.com





'/>"/>
SOURCE NeurogesX
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
2. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
3. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
4. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
5. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
6. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
7. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
8. NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
9. NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study
10. NeurogesX to Present at JMP Securities Healthcare Focus Conference
11. NeurogesX to Hold Conference Call to Discuss Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... India , February 22, 2017 ... Radio Synthesis Modules Market: Global Opportunity Analysis and Industry Forecast, ... worth $20 million in 2015 and projected to reach $32 ... 2016 to 2022. North America accounted ... and unit volumes, whereas Asia-Pacific region ...
(Date:2/22/2017)... A research report by Arcview Market Research focused on cannabis ... changing landscape of the legal market reveals that regulated cannabis sales ... , a 30% increase from 2015. According to the research ... 2021 representing a 26 percent compound annual growth rate. The use ... Canada is gradually becoming more mainstream thanks ...
(Date:2/22/2017)... Feb 22, 2017 Research and Markets has ... & Trends - Industry Forecast to 2025" report to their offering. ... The Global Clot Management ... over the next decade to reach approximately $2.1 billion by 2025. ... for all the given segments on global as well as regional levels ...
Breaking Medicine Technology:
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... launch of ProGen™ PRP, the latest innovation in the delivery of Platelet Rich ... care, aesthetics, cardiovascular and pain management, to accelerate tissue synthesis and provide a ...
(Date:2/22/2017)... ... February 22, 2017 , ... Forty-five percent of American ... that family members or friends have also commented about their poor hearing. However, ... hearing aids. One reason, suggested by 89 percent of American respondents, is that ...
(Date:2/22/2017)... ... February 22, 2017 , ... Pet obesity in the U.S. ... dogs, according to the Association for Pet Obesity Prevention (APOP). During the ninth annual ... issues such as the benefits of corn and grains, value of raw and organic ...
(Date:2/22/2017)... ... 22, 2017 , ... BrightStar Care Charleston , a home care and ... South Carolina (MUSC) Center on Aging’s Senior Expo on Thursday, March 23, 2017, ... a tremendous resource in our community. We are thrilled to participate in this event ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... - the Vector™ Series Multi-Cook Oven offers up to four ovens in one. ... Structured Air Technology™ for unmatched evenness in cooking. Alto-Shaam has partnered with Appliance ...
Breaking Medicine News(10 mins):